7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,372.58

+830.40

+1.08%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

Evaxion A/S (EVAX)

2.9300 -0.1500 (-4.87%)

At close: October 30 at 4:00:01 PM EDT

Loading Chart for EVAX

Chart Range Bar

Interval:

In partnership with ChartIQ

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading

European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ...

Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ...

Evaxion announces business update and second quarter 2026 financial results

Evaxion announces business update and second quarter 2026 financial results

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

European Equities Traded in the US Rise in Thursday Trading

European Equities Traded in the US Rise in Thursday Trading

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: